yahoo.comSEP 33 min read$MDT

4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Medtronic (MDT) reported 8.4% revenue growth in fiscal 2026, driven by cardiovascular business. It expects 7.25%-7.75% organic growth in fiscal 2027. Free cash flow rose 4.6% to $5.43B. The company offers a 3.1% yield and has raised dividends for 49 years. Analysts project 14% EPS growth from 2026-2029, with the stock trading at 18x forward earnings.

Original reporting

yahoo.com

Published Sep 3, 2026, 5:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 3, 2026, 5:22 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

4 Reasons to Buy Medtronic Stock Like There's No Tomorrow — source image — Source · yahoo.com

Decision brief

The 30-second read

$MDTBullishMed

Why it matters

The disclosed earnings beat and guidance could trigger buying pressure, especially from dividend‑focused funds.

Market read

First report of FY2026 results provides fresh material for traders; upside potential if market re‑prices growth narrative.

What to watch

Potential regulatory or reimbursement risks could temper upside.

Relevance 7/10Novelty 8/10Timing: post‑earnings release

Background

Medtronic has addressed supply‑chain and cost issues, spun off its diabetes unit, and is targeting dividend‑king status.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MDTBullishHigh confidence

Context

Fiscal 2026 revenue grew 8.4% to $36.4B and free cash flow rose 4.6% to $5.43B, indicating a turnaround.

Expected impact

Potential upside as investors re‑rate growth prospects.

Evidence & confidence

First‑time disclosure of strong FY2026 results and guidance suggests a material catalyst.

Market effects

Sector

Medical‑device sector may see renewed interest as a leading player shows growth.

Regional

U.S. healthcare stocks could benefit from MDT's upside.

Global

Limited to investors focused on U.S. med‑tech equities.

Counterpoint

What could challenge this read

Valuation still high relative to peers; growth may not sustain.

Key entities

Company
Medtronic
Global medical‑device manufacturer (NYSE: MDT).

Read at source ← All news

OCT 23

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

finance.yahoo.com2 min

OCT 22

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min

OCT 22

$MDTMedAI 8/10

Medtronic Reports Positive Real-World Data For Cardiac Ablation Systems

Medtronic (MDT) presented positive real-world data for its cardiac ablation systems at the APHRS 2026 meeting. The Sphere-9 catheter and PulseSelect PFA system showed low complication rates and high success rates in treating heart rhythm disorders. MDT stock closed at $93.03, up 0.25% in pre-market trading.

rttnews.com2 min

OCT 20

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

medicaldevice-network.com2 min

OCT 19

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.